REG - Cambridge Cognition - Launch of in-house rater training service

Cambridge Cognition HoldingsAnnouncement

21/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250121:nRSU0313Ua&default-theme=true

RNS Number : 0313U  Cambridge Cognition Holdings PLC  21 January 2025

 

21 January 2025

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition expands services with the launch of in-house Rater
Training

 

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group
specialising in digital products that advance brain health research and
treatment, is pleased to announce the launch of its in-house Rater Training
service.

Rater training is an important component of successful Central Nervous System
(CNS) clinical studies that ensure customers' clinical trial staff collect
reliable CNS study data. Adding in-house Rater Training to the Group's
electronic Clinical Outcome Assessments (eCOA) and Automated Quality Assurance
tools will enable the Company to become a single platform provider and expand
the size of the accessible CNS clinical trials market in which its products
can be utilised.

 

The global cognitive assessment and training healthcare market, encompassing
rater training services, delivered revenues of $5.2 billion in 2023 and,
notably, the services segment, which includes comprehensive rater training
solutions, captured more than 50% of the total market revenue(1). This market
is projected to grow at a compound annual growth rate of 27% through 2030(1).

 

Barbara Enger RN MSN, a CNS expert with 20 years of experience in eCOA service
delivery and a consultant for Cambridge Cognition, commented:

"Rater training is a critical and mandatory component of successful CNS
clinical studies. Raters must demonstrate thorough knowledge of the
administration and scoring of the endpoint instrument, and must achieve
acceptable levels of both intra rater and inter rater reliability prior to the
start of the study and continuing through the length of the study. Equally
important is the applied skill needed to administer and score the instrument
electronically.  Combining those training aspects helps to ensure the
collection of reliable study data."

 

Rob Baker, Joint Managing Director and Chief Operating Officer of Cambridge
Cognition, said:

"We believe the addition of Rater Training to our portfolio will open up new
markets for our world class brain health software tools, seamlessly supporting
raters with advanced technology and delivering the accuracy, efficiency, and
reliability that pharmaceutical companies seek in their CNS clinical trials.
We are pleased to have already secured Rater Training work recently  and
expect to roll out this offering to new and existing customers in the coming
weeks."

 

1. Grand View Research (2024) 'Cognitive Assessment And Training In Healthcare
Market Size, Share & Trends Analysis Report By Assessment (Biometrics, Pen
& Paper-based Assessment), By Component (Solution, Services), By
Application, By Region, And Segment Forecasts, 2024 - 2030', Report ID:
GVR-4-68039-994-2. San Francisco: Grand View Research.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                Tel: 012 2381 0700
 Rob Baker, Chief Operating Officer and Joint Managing Director

 Panmure Liberum   Limited (NOMAD and Joint Broker)              Tel: 020 7886 2968
 Freddy Crossley / Will Goode / Mark Rogers                      (Corporate Broking)
 Rupert Dearden                                                  (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                          Tel: 020 3903 7715
 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                            Tel: 020 7796 4133
 Dan de Belder / Hattie Dreyfus / Harry Griffiths                cog@hudsonsandler.com

 

Notes to Editors

 

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products that advance brain health research and treatment. The company
offers four core products: CANTAB® assessments-providing scientifically
validated, highly sensitive, precise, and objective measures of cognitive
function correlated to neural networks; a flexible and proven eCOA platform
with an extensive library of instruments, enabling efficient study setup and
scalable data capture; rater training services that standardise assessment
delivery and scoring across clinical trials and quality assurance tools that
ensure data integrity by automatically detecting deviations in administration
and scoring, saving time and money. These products collectively improve
clinical trial outcomes, enable early patient identification, and enhance
global efficiency in healthcare and pharmaceuticals.

 

For further information, visit: www.cambridgecognition.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.cambridgecognition.com%2F&data=05%7C02%7Chgriffiths%40hudsonsandler.com%7Cc696c6a3150d40f91a9508dcfdd13b58%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638664322305026349%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=vQVOIVxNQ8WYYOufDnSVKUH0oa7PLvXjnP0VT%2FzCfJc%3D&reserved=0)

 

Barbara Enger RN, MSN

 

Barbara Enger specializes in the area of central nervous system clinical
trials, specifically in the training and quality management of study site
investigators. Barbara has 20 years of CNS experience providing specialty
clinical services to pharmaceutical clients which includes 4 years as a study
site sub investigator in psychiatric and geriatric clinical trials. Prior to
Barbara's current position in the area of CNS clinical trials, she was an
advanced practice psychiatric nurse in general psychiatry, including dementia.
Barbara has an MSN in Psychiatric Nursing from the University of Pennsylvania,
where she held faculty appointments for 15 years.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBMMLTMTJTBMA